Skip to main content
Press Releases

Publication of ONM-100 Phase 1

Southlake, TX. – June 26, 2020 – OncoNano Medicine, Inc. announced today the publication of Phase 1
clinical trial data in Nature Communications featuring OncoNano’s intraoperative tumor imaging product
candidate, ONM-100. The study evaluated safety, pharmacokinetics and feasibility of ONM-100 in
image-guided surgery, occult tumor detection and visualization of tumor margins in four different
cancer types. Following tumor resection, ONM-100 detected residual tumor positive margins in 9 of 9
patients in whom histology confirmed tumor positive margins, and also detected occult lesions in an
additional 5 patients whose tumors were undetected by standard of care. The research paper, Exploiting
metabolic acidosis in solid cancers using a tumor-agnostic pH-activatable nanoprobe for fluorescenceguided surgery, will appear in the June 26 issue of Nature Communications.

Surgical resection remains a cornerstone treatment strategy for solid tumors today and incomplete
tumor removal can be predictive of cancer recurrence and metastasis. Despite imaging advances, there
are no approved imaging options to provide real-time feedback to surgeons that specifically target
tumor masses but are agnostic to cancer type. ONM-100, a pH-sensitive micelle conjugated to a
fluorescent tag, targets the relatively acidic pH of the tumor microenvironment – a universal biomarker
of solid tumors – to precisely label tumor masses. ONM-100 is intravenously administered prior to
surgery and visualized during surgery using existing surgical fluorescent imaging equipment. Exploiting
this universal biomarker of solid tumors confers the potential for ONM-100 to be used in various cancer
types, irrespective of tissue of origin.

“We are extremely pleased to have this critical work published in Nature Communications,” commented
Gooitzen Michell van Dam, MD, PhD, CEO of TRACER BV and professor at the University Medical Center
of Groningen, Netherlands. As Principal Investigator and corresponding author of the manuscript he
states, “ONM-100 was able to detect tumor positive resection margins and several cancerous lesions
that standard of care procedures missed in diverse types of solid cancers. We eagerly anticipate seeing
ONM-100’s potential further explored in Phase 2 clinical trials.”

“We are delighted to see the scientific community’s validation of ONM-100 that is demonstrated by this
acceptance in Nature Communications,” commented Ravi Srinivasan, PhD, Cofounder and CEO of
OncoNano. “ONM-100 has the potential to substantially simplify and enhance the effectiveness of
tumor resection surgeries, and given its possible tumor-agnostic applications, it may be used in broad
patient populations in the future. We look forward to this same pH-sensitive micelle technology being
utilized for other oncology applications, such as tumor-specific therapeutic delivery.”
ONM-100 is currently being evaluated in Phase 2 clinical trials in the United States in several unique
cancer indications, including breast, ovarian, prostate and colorectal cancers. Learn more about this trial

About ONM-100

ONM-100 is OncoNano’s lead product candidate that utilizes the pH-sensitive micelle platform to
encapsulate a fluorescent tag and exploit a universal biomarker of all solid cancers – the relatively acidic
pH of the tumor microenvironment – to intraoperatively image tumors. ONM-100 micelles remain
inactive at normal physiological pH until exposure to the acidic tumor microenvironment triggers micelle
dissociation and fluorescent tag expression, making tumors visible during surgery with standard surgical
imaging equipment. ONM-100 is currently in Phase 2 clinical trials. ONM-100 was partially funded for
clinical research by the Cancer Prevention and Research Institute of Texas.

About OncoNano Medicine

OncoNano Medicine is developing a new class of products that exploit pH as a biomarker to diagnose
and treat cancer with high specificity. Our product candidates are designed to help patients across the
continuum of cancer care and include solid tumor therapeutics, agents for real-time image-guided
surgery and a platform of product candidates that activate and guide the body’s immune system to
target cancer. Learn more at


Lauren Arnold